Performance status-1 - Slightly symptomatic Posts on Medivizor
Navigation Menu

Performance status-1 – Slightly symptomatic Posts on Medivizor

Looking for patients with newly diagnosed multiple myeloma to test a combination therapy

Posted by on Oct 31, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is evaluating the safety and effectiveness of the D-KRd regimen (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in patients with multiple myeloma. The main outcome to be measured will be the number of patients who respond to treatment. This study is recruiting in Chicago, Illinois. The details Multiple myeloma (MM)...

Read More

Looking for patients with colorectal cancer to test a new therapy with tumor infiltrating lymphocytes

Posted by on Oct 31, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness of tumor-infiltrating lymphocytes (TIL) in the treatment of colorectal cancer. The main outcome to be measured is the tumor response to the treatment. This trial will be conducted in Texas, US. The details Cancer is one of the leading causes of death worldwide. Therapy such as...

Read More

Can adding chemotherapy agents to gefitinib improve outcomes for advanced NSCLC?

Posted by on Oct 28, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated whether adding chemotherapy agents to gefitinib (Iressa) improved outcomes for patients with advanced non-small cell lung cancer (NSCLC). This study found that this combination improved survival but increased side effects for these patients. Some background The gene for epidermal growth factor receptor...

Read More

Looking for patients with metastatic triple-negative breast cancer to trial experimental vaccine with biological therapy

Posted by on Sep 20, 2019 in Breast cancer | 0 comments

In a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...

Read More

Looking for patients with advanced colorectal cancer to test an experimental treatment

Posted by on Sep 10, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as colorectal cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More

Looking for patients with advanced triple negative breast cancer to test a new treatment

Posted by on Sep 10, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with solid tumors such as triple-negative breast cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More

Looking for patients with BRAF positive inoperable colorectal cancer to test a new treatment combination

Posted by on Aug 14, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the best dose and side effects of a combined treatment with encorafenib (Braftovi), cetuximab (Erbitux) and nivolumab (Opdivo). The main outcome to be measured will be the tumor response to the treatment. This trial is being conducted in Texas, US. The details Colorectal cancer is one of the leading...

Read More

Looking for patients with relapsed multiple myeloma to test a biological drug and immune cell vaccine

Posted by on Jul 31, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial is investigating the effectiveness and side effects of nivolumab (Opdivo) with a dendritic cell vaccine for patients with multiple myeloma (MM). The main outcome of this study would be to see the number of patients that develop an allergic reaction to the treatment. This study is recruiting in Boston, MA, United...

Read More